PCM
JAZZ icon

Portolan Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Portolan Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-35,898
Closed -$5.07M – 116
2016
Q2 		$5.07M Buy
+35,898
New +$5.29M 0.73% 56

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Portolan Capital Management's JAZZ Position: Q3 2016 in Review

Portolan Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2016, closing a stake of 35,898 shares — an estimated $5.07M sold.

Portolan Capital Management first reported a position in JAZZ in Q2 2016 and held it in 1 quarter. The position peaked at $5.07M in Q2 2016. 325 funds tracked by Wall St. Rank hold JAZZ as of Q3 2016.

  • Portolan Capital Management reported no remaining Jazz Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Portolan Capital Management sold 35,898 Jazz Pharmaceuticals shares in Q3 2016, an estimated $5.07M.
  • Portolan Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Portolan Capital Management's Jazz Pharmaceuticals position peaked at $5.07M in Q2 2016.
  • 325 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2016.

Based on Portolan Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.